Journal article
Cathelicidin Peptides Inhibit Multiply Antibiotic-Resistant Pathogens from Patients with Cystic Fibrosis
Antimicrobial agents and chemotherapy, Vol.45(10), pp.2838-2844
10/2001
DOI: 10.1128/AAC.45.10.2838-2844.2001
PMCID: PMC90740
PMID: 11557478
Abstract
Endogenous peptide antibiotics are under investigation as inhaled therapeutic agents for cystic fibrosis (CF) lung disease. The bactericidal activities of five cathelicidin peptides (LL37 [human], CAP18 [rabbit], mCRAMP [mouse], rCRAMP [rat], and SMAP29 [sheep]), three novel alpha-helical peptides derived from SMAP29 and termed ovispirins (OV-1, OV-2, and OV-3), and two derivatives of CAP18 were tested by broth microdilution assays. Their MICs were determined for multiply antibiotic-resistant
Pseudomonas aeruginosa
(
n
= 24),
Burkholderia cepacia
(
n
= 5),
Achromobacter xylosoxidans
(
n
= 5), and
Stenotrophomonas maltophilia
(
n
= 5) strains isolated from CF patients. SMAP29 was most active and inhibited mucoid and nonmucoid
P. aeruginosa
strains (MIC, 0.06 to 8 μg/ml). OV-1, OV-2, and OV-3 were nearly as active (MIC, 0.03 to 16 μg/ml), but CAP18 (MIC, 1.0 to 32 μg/ml), CAP18-18 (MIC, 1.0 to >32 μg/ml), and CAP18-22 (MIC, 0.5 to 32 μg/ml) had variable activities. LL37, mCRAMP, and rCRAMP were least active against the clinical isolates studied (MIC, 1.0 to >32 μg/ml). Peptides had modest activities against
S. maltophilia
and
A. xylosoxidans
(MIC range, 1.0 to > 32 μg/ml), but none inhibited
B. cepacia
. However, CF sputum inhibited the activity of SMAP29 substantially. The effects of peptides on bacterial cell membranes and eukaryotic cells were examined by scanning electron microscopy and by measuring transepithelial cell resistance, respectively. SMAP29 caused the appearance of bacterial membrane blebs within 1 min, killed
P. aeruginosa
within 1 h, and caused a dose-dependent, reversible decrease in transepithelial resistance within 5 h. The tested cathelicidin-derived peptides represent a novel class of antimicrobial agents and warrant further development as prophylactic or therapeutic agents for CF lung disease.
Details
- Title: Subtitle
- Cathelicidin Peptides Inhibit Multiply Antibiotic-Resistant Pathogens from Patients with Cystic Fibrosis
- Creators
- Lisa Saiman - Department of Pediatrics, Columbia University, New York, New YorkSetareh Tabibi - Department of Pediatrics, Columbia University, New York, New YorkTimothy D Starner - Department of Pediatrics, Columbia University, New York, New YorkPablo San Gabriel - Department of Pediatrics, Columbia University, New York, New YorkPatricia L Winokur - Department of Pediatrics, Columbia University, New York, New YorkHong Peng Jia - Department of Pediatrics, Columbia University, New York, New YorkPaul B McCray - Department of Pediatrics, Columbia University, New York, New YorkBrian F Tack - Department of Pediatrics, Columbia University, New York, New York
- Resource Type
- Journal article
- Publication Details
- Antimicrobial agents and chemotherapy, Vol.45(10), pp.2838-2844
- DOI
- 10.1128/AAC.45.10.2838-2844.2001
- PMID
- 11557478
- PMCID
- PMC90740
- NLM abbreviation
- Antimicrob Agents Chemother
- ISSN
- 0066-4804
- eISSN
- 1098-6596
- Publisher
- American Society for Microbiology
- Language
- English
- Date published
- 10/2001
- Academic Unit
- Microbiology and Immunology; Pulmonary Medicine; Infectious Diseases; Stead Family Department of Pediatrics; Medicine Administration; Internal Medicine
- Record Identifier
- 9984093209302771
Metrics
30 Record Views